Equibles does not estimate personal net worth.
Get an email with a short summary when Enanta Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get ENTA alertsJay Luly is recorded as CEO at Enanta Pharmaceuticals Inc (ENTA). Jay Luly has spoken on 15 earnings calls and 1 other investor event across 1 company, most recently for Enanta Pharmaceuticals Inc on September 15, 2026. Enanta Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Enanta Pharmaceuticals Inc includes Harry R. Trout, III (CFO), Paul Mellett (CFO), Tara L. Kieffer, Ph.D. (COO) and 5 others.
“Before I begin, I want to remind you I'll be making some forward-looking statements. And for a summary of the risks associated with these statements, please see our filings on sec.gov and on our website.”
“Throughout 2024, Enanta has remained squarely focused on advancing our virology and immunology pipeline to bring important oral therapeutics to market. Our commitment to developing treatments for areas of high unmet need is driven by our mission to transform patients' lives with curative therapies.”
“In the first quarter of 2024, Enanta began an important year, which has the potential to advance our programs in both virology and immunology and drive value across the company.”
“In fiscal 2023, Enanta took important steps leading to meaningful progress in addressing the unmet need for treating serious respiratory viruses and advancing our business objectives.”
“At Enanta, we are committed to our mission of being a leader in the development of groundbreaking therapeutics for viral infections, and this quarter we made important strides to bring us closer to impactful inflection points and ultimately our goals.”
Biotechnology · Healthcare
CEO
